Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of asymptomatic multiple myeloma as defined by the criteria below:~* Presence of bone marrow clonal plasma cells (more than 10%)~* Presence of an M-protein in serum and/or urine (no concentration specified)~* Serum calcium \< 12 mg/dl within 14 days prior to registration. Less than 3 lytic lesions, no pathologic fractures and no osteopenia noted on skeletal survey~* No symptoms of hyperviscosity, amyloidosis or recurrent infection~* Bone mineral density with a T score higher than -2.0 standard deviation (not have osteoporosis) within 28 days prior to registration~* Negative pregnancy test~Exclusion Criteria:~* No previous treatment with bisphosphonates~* No disorders of the parathyroid or thyroid glands~* No current breastfeeding~* No prior malignancy is allowed except for adequately treated in situ cervical cancer, Gleason \< grade 7 prostate cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
- B (Type: NO_INTERVENTION): Patients will be randomly assigned by study number to observation only.

Based on this trial design, predict the completion outcome and termination type (if applicable).